Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
Bhopal: Bhopal Memorial Hospital & Research Center (BMHRC) will close two main offices.
Read Full NewsUse of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
The therapy also received orphan drug designation from the FDA.
Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease
HCPLive 5 Stories in Under 5: Week of 01/11
Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars
1.
iPSC-based vaccines: A new hope for preventing and treating colorectal cancer
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
More evidence links physical activity with improved cancer survival
4.
Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.
5.
Distribution of fat could influence cancer risk, study suggests
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management
3.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
4.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
5.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
2.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge